Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,482 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.
Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T, Hirata H, Yano Y, Yokota S, Kinehara Y, Naito Y, Otsuka T, Kanazu M, Kuroyama M, Hamaguchi M, Koba T, Futami Y, Ishijima M, Suga Y, Akazawa Y, Machiyama H, Iwahori K, Takamatsu H, Nagatomo I, Takeda Y, Kida H, Akbay EA, Hammerman PS, Wong KK, Dranoff G, Mori M, Kijima T, Kumanogoh A. Osa A, et al. Among authors: hirata h. JCI Insight. 2018 Oct 4;3(19):e59125. doi: 10.1172/jci.insight.59125. JCI Insight. 2018. PMID: 30282824 Free PMC article.
Anti-fibrotic effects of theophylline on lung fibroblasts.
Yano Y, Yoshida M, Hoshino S, Inoue K, Kida H, Yanagita M, Takimoto T, Hirata H, Kijima T, Kumagai T, Osaki T, Tachibana I, Kawase I. Yano Y, et al. Among authors: hirata h. Biochem Biophys Res Commun. 2006 Mar 17;341(3):684-90. doi: 10.1016/j.bbrc.2006.01.018. Epub 2006 Jan 18. Biochem Biophys Res Commun. 2006. PMID: 16430859
Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism.
Kijima T, Shimizu T, Nonen S, Furukawa M, Otani Y, Minami T, Takahashi R, Hirata H, Nagatomo I, Takeda Y, Kida H, Goya S, Fujio Y, Azuma J, Tachibana I, Kawase I. Kijima T, et al. Among authors: hirata h. J Clin Oncol. 2011 Jul 1;29(19):e588-90. doi: 10.1200/JCO.2010.34.3368. Epub 2011 Apr 18. J Clin Oncol. 2011. PMID: 21502555 No abstract available.
Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.
Kijima T, Takeuchi K, Tetsumoto S, Shimada K, Takahashi R, Hirata H, Nagatomo I, Hoshino S, Takeda Y, Kida H, Goya S, Tachibana I, Kawase I. Kijima T, et al. Among authors: hirata h. Cancer Sci. 2011 Aug;102(8):1602-4. doi: 10.1111/j.1349-7006.2011.01970.x. Cancer Sci. 2011. PMID: 21767331 Free article.
Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.
Takahashi R, Hirata H, Tachibana I, Shimosegawa E, Inoue A, Nagatomo I, Takeda Y, Kida H, Goya S, Kijima T, Yoshida M, Kumagai T, Kumanogoh A, Okumura M, Hatazawa J, Kawase I. Takahashi R, et al. Among authors: hirata h. Clin Cancer Res. 2012 Jan 1;18(1):220-8. doi: 10.1158/1078-0432.CCR-11-0868. Epub 2011 Oct 21. Clin Cancer Res. 2012. PMID: 22019513
Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis.
Ihara S, Kida H, Arase H, Tripathi LP, Chen YA, Kimura T, Yoshida M, Kashiwa Y, Hirata H, Fukamizu R, Inoue R, Hasegawa K, Goya S, Takahashi R, Minami T, Tsujino K, Suzuki M, Kohmo S, Inoue K, Nagatomo I, Takeda Y, Kijima T, Mizuguchi K, Tachibana I, Kumanogoh A. Ihara S, et al. Among authors: hirata h. Cancer Res. 2012 Jun 15;72(12):2990-9. doi: 10.1158/0008-5472.CAN-11-4062. Epub 2012 Jun 1. Cancer Res. 2012. PMID: 22659452
1,482 results